SCHEMBL2747258

SCHEMBL2747258

CNc1nccc(Oc2ccc3c(C(=O)Nc4ccc(OC(F)(F)F)cc4)cccc3c2F)n1

nearest known ligand 0.58

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
KDR P35968 18/20 0.58
BRAF P15056 1/20 0.49
MAPK14 Q16539 1/20 0.49
TNNI3K Q59H18 1/20 0.49
FLT1 P17948 1/20 0.44
FLT4 P35916 1/20 0.44
ABL1 P00519 1/20 0.44
AURKB Q96GD4 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4548780 0.85 KDR (0.79) KDRFLT1FLT4
SCHEMBL2747025 0.84 KDR (0.55) KDRBRAFMAPK14TNNI3KFLT1
SCHEMBL4548719 0.84 KDR (0.55) KDRBRAFMAPK14TNNI3KFLT1
SCHEMBL2747170 0.83 KDR (0.54) KDRBRAFMAPK14TNNI3KFLT1
SCHEMBL2749014 0.83 KDR (0.60) KDRBRAFMAPK14TNNI3KFLT1
SCHEMBL2747095 0.83 KDR (0.59) KDRBRAFMAPK14TNNI3KFLT1
SCHEMBL2747385 0.82 KDR (0.57) KDRBRAFMAPK14TNNI3KFLT1
SCHEMBL2748268 0.81 KDR (0.46) KDRBRAFMAPK14TNNI3KAURKB
SCHEMBL2747275 0.77 KDR (0.83) KDRFLT1
SCHEMBL4548773 0.77 KDR (0.79) KDRBRAFMAPK14TNNI3KFLT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8178557-B2 Compounds and methods of use AMGEN INC. (US) 2012-05-15 US disclosed
US-8178557-B2 Compounds and methods of use AMGEN INC. (US) 2012-05-15 US disclosed
US-8178557-B2 Compounds and methods of use AMGEN INC. (US) 2012-05-15 US disclosed
US-20090176774-A1 Compounds and methods of use AMGEN INC. (US) 2009-07-09 US disclosed
US-20090176774-A1 Compounds and methods of use AMGEN INC. (US) 2009-07-09 US disclosed
US-20090176774-A1 Compounds and methods of use AMGEN INC. (US) 2009-07-09 US disclosed
US-7435823-B2 Compounds and methods of use AMGEN INC. (US) 2008-10-14 US disclosed
US-7435823-B2 Compounds and methods of use AMGEN INC. (US) 2008-10-14 US disclosed
US-7435823-B2 Compounds and methods of use AMGEN INC. (US) 2008-10-14 US disclosed
US-20060241115-A1 Compounds and methods of use AMGEN INC. 2006-10-26 US disclosed
EP-1713484-A2 COMPOUNDS AND METHODS OF USE AMGEN INC. (US) 2006-10-25 EP disclosed
WO-2005070891-A2 COMPOUNDS AND METHODS OF USE AMGEN INC (US) 2005-08-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060241115-A1 Compounds and methods of use HGF, HGFAC, MET KDR 354/4885BRAF 170/4885MAPK14 1944/4885
US-20090176774-A1 Compounds and methods of use HGF, HGFAC, MET KDR 354/4885BRAF 170/4885MAPK14 1944/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.